CWHM-117
CWHM-117 is an orally active aspartic protease inhibitor with selective activity against Toxoplasma gondii. CWHM-117 inhibits the proliferation of Toxoplasma gondii tachyzoites in human fibroblasts, with an EC50 of 2.00 µM. CWHM-117 delays mortality in an acute mouse model of toxoplasmosis. In a chronic mouse model of toxoplasmosis, CWHM-117 reduces brain cyst burden and prolongs survival. CWHM-117 can be used for research on toxoplasmosis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1505452-80-1
- 화학식: C23H27N3O3
- 분자량:393.48
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Parasite Isoforms
More
Biological Activity
제품 설명
IC50 & Target
[1]|
Toxoplasma 2 μM (EC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HFF | EC50 |
2.00 μM
|
Inhibition of intracellular Toxoplasma gondii RH-2F1 tachyzoite proliferation in human foreskin fibroblasts (HFF) incubated for 72 h post-infection, measured by β-galactosidase activity using chlorophenol red-β-D-galactopyranoside (CPRG) as substrate.
Inhibition of intracellular Toxoplasma gondii RH-2F1 tachyzoite proliferation in human foreskin fibroblasts (HFF) incubated for 72 h post-infection, measured by β-galactosidase activity using chlorophenol red-β-D-galactopyranoside (CPRG) as substrate.
|
PMC13435739 |
| HFF | CC50 |
14.30 μM
|
Cytotoxicity against human foreskin fibroblasts (HFF) incubated for 72 h, assessed by cell viability measured via resazurin assay.
Cytotoxicity against human foreskin fibroblasts (HFF) incubated for 72 h, assessed by cell viability measured via resazurin assay.
|
PMC13435739 |
In Vitro
CWHM-117 (0.39-100 μM; 72 h) potently inhibits intracellular proliferation of T. gondii RH-2F1 tachyzoites in HFF cells with an EC50 of 2.00 μM[1].
CWHM-117 (0.39-100 μM; 72 h) has a CC50 of 14.30 μM against HFF cells, with a selectivity index of 7.15 for T. gondii tachyzoites[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
CWHM-117 (150 mg/kg/day; p.o.; once daily; 5 consecutive days) significantly reduces cerebral cyst burden in a murine chronic toxoplasmosis model, demonstrating activity against the latent bradyzoite stage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss mice (5-6 week old) were infected intraperitoneally with 2 × 105 freshly egressed T. gondii tachyzoites (RH strain)[1]
-
Dosage:150 mg/kg/day
-
Administration:p.o.; once daily; 10 consecutive days
-
Result:Delayed mortality, with treated animals surviving up to day 11 post-infection compared to vehicle-treated animals that succumbed between days 7 and 9 post-infection.
Showed no significant weight loss compared to the vehicle group.
-
Animal Model:Swiss mice (5-6 week old) were orally infected with 10 brain cysts of T. gondii (ME-49 strain)[1]
-
Dosage:150 mg/kg/day
-
Administration:p.o.; once daily; 5 consecutive days
-
Result:Caused a marked, statistically significant reduction in the number of brain cysts compared to the vehicle-treated group.
Chemical Information
-
CAS No. 1505452-80-1
-
분자량 393.48
-
화학식 C23H27N3O3
-
SMILES
N=C(NC1(C2=CC=C(OC)C=C2)C3=CC=C(OC)C=C3)N(C4CCCCC4)C1=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)